Bio-Path Holdings Inc (NASDAQ:BPTH) shares rose 22.2% during mid-day trading on Tuesday . The company traded as high as $18.59 and last traded at $18.00. Approximately 636,812 shares changed hands during trading, a decline of 78% from the average daily volume of 2,842,780 shares. The stock had previously closed at $14.73.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Gainplan LLC purchased a new position in Bio-Path in the first quarter valued at $204,000. Virtu Financial LLC purchased a new position in Bio-Path in the first quarter valued at $336,000. Finally, BlackRock Inc. increased its holdings in Bio-Path by 431.0% in the first quarter. BlackRock Inc. now owns 39,901 shares of the company’s stock valued at $813,000 after buying an additional 32,386 shares in the last quarter.
TRADEMARK VIOLATION WARNING: This piece was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/14/bio-path-bpth-stock-price-up-22-2.html.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Story: What is net income?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.